Researchers from the University of Barcelona and collaborators reported the discovery and preclinical characterization of novel imidazoline I2 receptor ligands (I2-IRs). Among the series, the most potent compound, [I], had a Ki value of 1.05 nM for the I2-IR and no I2/α2 selectivity.